Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herberman

Showing results (491-500 of 546) with videos related to

Pageof 55
Sort By:
European Journal of Immunology|October 3, 1999
Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cellsD Metes, M Manciulea, D Pretrusca, et al.
Cancer Research|August 3, 2007
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinomaShuang Wei, Ilona Kryczek, Robert P Edwards, et al.
Disaster Health|February 24, 2017
Mitigating flood exposure: Reducing disaster risk and trauma signatureJames M Shultz, Andrew McLean, Holly B Herberman Mash, et al.
Journal of the National Cancer Institute|July 1, 1975
Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanomaJ L McCoy, L F Jerome, J H Dean, et al.
Cancer Research|September 15, 1989
Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma linesD S Heo, C Snyderman, S M Gollin, et al.
Psychiatric Services (Washington, D.C.)|December 3, 2013
Suicidal behaviors and the use of mental health services among active duty Army soldiersJodi B A McKibben, Carol S Fullerton, Holly B Herberman Mash, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 5, 2011
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicFrank L Meyskens, Gregory A Curt, Dean E Brenner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1985
Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2J E Talmadge, R B Herberman, M A Chirigos, et al.
Journal of the National Cancer Institute|November 1, 1979
Immunologic abnormalities in melanoma-prone familiesJ H Dean, M H Greene, R R Reimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusionR P Edwards, W Gooding, B C Lembersky, et al.
Pageof 55

Showing results (491-500 of 546) with videos related to

Sort By:
Pageof 55
European Journal of Immunology|October 3, 1999
Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cellsD Metes, M Manciulea, D Pretrusca, et al.
Cancer Research|August 3, 2007
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinomaShuang Wei, Ilona Kryczek, Robert P Edwards, et al.
Disaster Health|February 24, 2017
Mitigating flood exposure: Reducing disaster risk and trauma signatureJames M Shultz, Andrew McLean, Holly B Herberman Mash, et al.
Journal of the National Cancer Institute|July 1, 1975
Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanomaJ L McCoy, L F Jerome, J H Dean, et al.
Cancer Research|September 15, 1989
Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma linesD S Heo, C Snyderman, S M Gollin, et al.
Psychiatric Services (Washington, D.C.)|December 3, 2013
Suicidal behaviors and the use of mental health services among active duty Army soldiersJodi B A McKibben, Carol S Fullerton, Holly B Herberman Mash, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 5, 2011
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicFrank L Meyskens, Gregory A Curt, Dean E Brenner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1985
Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2J E Talmadge, R B Herberman, M A Chirigos, et al.
Journal of the National Cancer Institute|November 1, 1979
Immunologic abnormalities in melanoma-prone familiesJ H Dean, M H Greene, R R Reimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusionR P Edwards, W Gooding, B C Lembersky, et al.
Pageof 55